NCT00102635 - 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 20, 2005

Primary Completion Date

January 31, 2006

Study Completion Date

November 30, 2006

Conditions

Head and Neck Cancer

Interventions

DRUG

Fenretinide (4-HPR)

Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.

DRUG

SCH66336

Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.

Trial Locations (1)

UT MD Anderson Cancer Center, Houston